Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Please Try Again

Password Hint : {{passwordHint}}

Remember me

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by RalphRalphon Aug 19, 2020 11:24pm

241 Views

Post# 31431855

RE:Acquistions out there ...

Momenta and Antibe are two totally different companies; their pipelines are vastly different. There are virtually no material similarities between the two. Momenta's acquisition valuation has no relevance to Antibe's potential valuation. Comparing the total overall markets that they are respectively pursuing is an extreme oversimplification.

MUGMODs wrote: As brought to my attention by EOJ123 on a different site, J&J strikes $6.5B deal for Momenta.

The deal gives J&J's Janssen unit access to Momenta's experimental therapy, nipocalimab, being tested for myasthenia gravis, a neuromuscular disease that causes weakness in muscles, and other diseases where the immune system attacks the body.

J&J hopes to get the drug approved to treat several conditions and eventually bring in blockbuster sales, as the company bulks up its pharmaceuticals unit, its largest business.

Similarly, Antibe is bringing 346 to Phase 3 in a $16B market for OA but are also planning to chase other indications in short order.

More investigation is needed to see how similar or how different Momenta and Antibe are ... but ... this might help us understand what kind of deals are possible. This also follows on the heals of a $400MM deal at Quest Pharmatech that saw it's lead drug for ovarian cancer get picked up by a South Korean company. The South Korean company was going to cover the Phase 3 costs for that drug as well.

Interesting !